Navigation Links
Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
Date:11/13/2012

HAYWARD, Calif., Nov. 13, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced additional data from its Phase 2b PEARL-SC study presented in a late breaking poster at the 2012 Annual Scientific Meeting of the American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP). The poster entitled "Blisibimod, an Inhibitor of B cell Activating Factor, in Patients with Moderate-to-Severe Systemic Lupus Erythematosus," was presented by Dr. Richard Furie, MD, on Tuesday, November 13, 2012. Dr. Furie is Chief of the Division of Rheumatology and Allergy-Clinical Immunology at the North Shore-Long Island Jewish Health System and directs the hospital's Systemic Lupus Erythematosus (SLE) and Autoimmune Disease Treatment Center.

The poster highlights data from the PEARL-SC clinical study including new information regarding treatment effects in the broader modified intent to treat population of lupus patients where 200 mg weekly blisibimod therapy was associated with statistically significant benefits in predefined SLE Responder Index (SRI*) endpoints. Specifically, this new data indicates statistically significant treatment effects using higher thresholds of improvement in disease score (SELENA/SLEDAI** reductions of 7 and 8) including the recently FDA reviewed SRI-8 endpoint to be utilized in the phase 3 CHABLIS-SC clinical studies. These data confirm and expand on previously reported clinical improvements seen in the population of patients to be enrolled in the CHABLIS-SC phase 3 clinical studies. These studies will enroll patients with active disease (SELENA/SLEDAI > 10) who are also receiving corticosteroid therapy at baseline.

As well, the poster highlighted the positive effect
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
2. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
3. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
4. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
5. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
7. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
8. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
9. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
10. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
11. Anthera Announces First Quarter 2012 Financial Report and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Kan. , Dec. 18, 2014   ... ), a biopharmaceutical company focused on the licensing, ... animals, today announced positive results from its pivotal ... drug for treating pain in dogs with osteoarthritis. ... in pain assessment scores that were statistically significant ...
(Date:12/19/2014)... robust development with the growth pace keeping at 20%-30% in ... the size of China separating membrane ... to 16.3%. It is projected that China ... around 20% in the upcoming years and that the figure ... An integrated membrane industrial system has taken shape in ...
(Date:12/17/2014)... , Alemania, December 17, 2014 ... año anterior, con un alto nivel de gasto en ... año fiscal 2013/14 (finalizado el 30 de septiembre de ... ciento a 4.287 millones de euros (año anterior: 4.190 ... la moneda desfavorables. Las ganancias (EBIT) crecieron un 14 ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3ZEISS confirma su posición en un entorno difícil 2
(Date:12/19/2014)... 19, 2014 From November 24, 2014, ... for the year 2014 in its Goa retreat . ... Through the Indian winters, from November to March, Siddhi Yoga ... beach of Arambol, Goa. The Goa training sessions will conclude ... of yoga teacher training, the 10th intake is also a ...
(Date:12/19/2014)... This is a professional and in-depth study ... with a focus on the Chinese market. The report ... Gliquidone manufacturers and is a valuable source of guidance ... industry. , Firstly, the report provides a basic overview ... technology. Then, the report explores the international and Chinese ...
(Date:12/19/2014)... (HealthDay News) -- Being in good shape seems to reduce ... looked at data from more than 57,000 Americans, including more ... between 1991 and 2009. Those in the poorest shape ... blood pressure at the start of the study, compared to ... fitness. Of the more than 8,000 people diagnosed with ...
(Date:12/19/2014)... Amy Norton HealthDay Reporter ... born to moms who were exposed to high levels of ... of developing autism, a U.S. study suggests. Researchers found ... 1990 and 2002, those exposed to the most air pollution ... who later developed autism. And exposure during the third trimester, ...
(Date:12/19/2014)... (HealthDay News) -- Prostaglandin analogue eye drops -- a ... risk of vision loss in patients with the eye ... by David Garway-Heath, of the Moorfields Eye Hospital and ... more than 500 people newly diagnosed with open-angle glaucoma ... one of the leading causes of blindness. About ...
Breaking Medicine News(10 mins):Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 2Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2
... in China is smaller than that of many other countries, ... diabetics// of age between 20 and 79 in 2003. ... in China, while diabetics are mostly aged between 60 to ... Department in Beijing University People's Hospital. ,"Although no ...
... the Mecca of Fashion, Paris, have uncovered a mechanism ... natural chemical called opiorphin//, a natural pain alleviator, far ... their experiments, rodents were found to experience pain relief ... with the usual dosage of morphine. The finding which ...
... with incriminating evidence that warns non-vegetarians who binge on red ... out that eating more than one and a half servings ... breast cancer and another study that vitamin supplements seem ... diseases except for vitamin C which seems to show some ...
... fatty acid known as docosahexaenoic acid (DHA) in their ... dementia and Alzheimer’s disease, according to a study. ... been found to increase the risk of dementia and ... of cases of dementia in the elderly, according to ...
... Shelnutt and Yujiang Song from Sandia National Laboratories have ... attaches //to a cell which involves a new process that ... Security Administration laboratory. ,An upcoming issue of the German ... Angewandte Chemie Int. Ed which has currently published the same ...
... be just a matter of eating a salad a day. ... Americans will welcome a new study that could keep them ... study, conducted by the UCLA School of Public Health and ... revealed eating salads with salad dressing and raw vegetables is ...
Cached Medicine News:Health News:Red alert to women against red meat consumption 2Health News:Higher Level of Certain Fatty Acid Associated with Lower Dementia Risk 2Health News:Novel methods to view how a drug attaches to a cell 2Health News:A Salad a Day Keeps the Doctor Away This Winter 2
... RX600 is a versatile, fully powered orthopaedic ... built-in traction facilities, a powered centre break ... extremely versatile too. ,<br.,In fact the RX600 ... as it is for traction procedures. The ...
... For complete orthopedic trauma procedures. ... system, the orthopedic trauma table top ... for easy patient positioning and provides ... key trauma procedures: hip pinnings; femur, ...
... The EXOGEN 2000+ device provides a ... nonunion or the acceleration of fresh ... home for 20 minutes daily, or ... your physician determines your fracture to ...
... cannulated interference screws have a ... screw divergence. Screws are available ... lengths. Screws are supplied sterile, ... and 9mm dia. (screws are ...
Medicine Products: